Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 66 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,057,000 | -4.7% | 212,018 | 0.0% | 0.09% | -11.0% |
| Q2 2022 | $3,208,000 | -79.1% | 212,018 | -40.3% | 0.10% | -59.8% |
| Q2 2020 | $15,352,000 | +27.0% | 355,366 | -32.0% | 0.25% | -21.0% |
| Q1 2020 | $12,085,000 | -31.2% | 522,480 | -7.1% | 0.32% | -9.7% |
| Q4 2019 | $17,570,000 | -21.1% | 562,237 | -34.2% | 0.35% | -41.8% |
| Q3 2019 | $22,280,000 | – | 854,940 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |